OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.65 USD | +17.86% |
|
0.00% | +9.27% |
| May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,180 | 1,715 | 1,184 | 648.2 | 532.1 | 782 | - | - |
| Enterprise Value (EV) 1 | 1,707 | 1,500 | 1,173 | 791.1 | 809.5 | 1,033 | 932 | 852 |
| P/E ratio | 10.1 x | -20.4 x | -5.3 x | -3.65 x | -4.14 x | -11.6 x | -24.4 x | 14.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.58 x | 2.58 x | 2.1 x | 1.04 x | 0.83 x | 1.28 x | 1.04 x | 0.86 x |
| EV / Revenue | 2.02 x | 2.26 x | 2.08 x | 1.27 x | 1.27 x | 1.69 x | 1.24 x | 0.94 x |
| EV / EBITDA | 6.27 x | 79 x | -7.28 x | -6.87 x | -24.9 x | 19.8 x | 11.1 x | 5.04 x |
| EV / FCF | 6.7 x | -8.7 x | -4.16 x | -4.38 x | 7.65 x | 1,033 x | 30.1 x | 8.44 x |
| FCF Yield | 14.9% | -11.5% | -24% | -22.8% | 13.1% | 0.1% | 3.33% | 11.9% |
| Price to Book | 3.07 x | 3.08 x | 3.39 x | 3.34 x | 9.03 x | 9.74 x | 5.52 x | 3.85 x |
| Nbr of stocks (in thousands) | 34,711 | 34,295 | 34,328 | 34,368 | 34,421 | 34,450 | - | - |
| Reference price 2 | 62.80 | 50.00 | 34.50 | 18.86 | 15.46 | 22.70 | 22.70 | 22.70 |
| Announcement Date | 1/30/20 | 1/28/21 | 1/27/22 | 1/26/23 | 2/8/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 844.8 | 663.6 | 565 | 624.3 | 638.8 | 611.4 | 749.6 | 909.9 |
| EBITDA 1 | 272.1 | 19 | -161 | -115.2 | -32.5 | 52.3 | 84.1 | 168.9 |
| EBIT 1 | 231.2 | -19.9 | -214.1 | -183.9 | -109.5 | -30.1 | 11 | 100.9 |
| Operating Margin | 27.37% | -3% | -37.89% | -29.46% | -17.14% | -4.92% | 1.47% | 11.09% |
| Earnings before Tax (EBT) 1 | 227.9 | -38.3 | -222.5 | -170.4 | -140.3 | -72 | -33.6 | 56.4 |
| Net income 1 | 219.1 | -84.4 | -223.5 | -177.6 | -128.3 | -67 | -31.9 | 52.4 |
| Net margin | 25.94% | -12.72% | -39.56% | -28.45% | -20.08% | -10.96% | -4.26% | 5.76% |
| EPS 2 | 6.200 | -2.450 | -6.510 | -5.170 | -3.730 | -1.950 | -0.9300 | 1.520 |
| Free Cash Flow 1 | 255 | -172.4 | -281.9 | -180.5 | 105.8 | 1 | 31 | 101 |
| FCF margin | 30.18% | -25.98% | -49.89% | -28.91% | 16.56% | 0.16% | 4.14% | 11.1% |
| FCF Conversion (EBITDA) | 93.72% | - | - | - | - | 1.91% | 36.86% | 59.8% |
| FCF Conversion (Net income) | 116.39% | - | - | - | - | - | - | 192.75% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 1/30/20 | 1/28/21 | 1/27/22 | 1/26/23 | 2/8/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 144 | - | 156.1 | 158.8 | 157.7 | 156.1 | 166 | 139.3 | 158.9 | 158.1 | 155 |
| EBITDA 1 | -48.5 | - | -53.1 | -41.1 | 5.6 | -9.5 | 12.4 | 15.9 | 18.4 | 9.1 | 8.9 |
| EBIT 1 | -64.1 | - | -71.1 | -59.3 | -12.9 | -28.6 | -8.6 | -4.7 | -2.2 | -11.5 | -11.7 |
| Operating Margin | -44.51% | - | -45.55% | -37.34% | -8.18% | -18.32% | -5.18% | -3.37% | -1.38% | -7.27% | -7.55% |
| Earnings before Tax (EBT) 1 | - | - | -95.5 | -68.5 | -15.8 | -36.6 | -19.5 | -9.8 | -14.7 | -24 | -23.2 |
| Net income 1 | -66 | -26.5 | -91.8 | -63.9 | -12.6 | -33.3 | -18.6 | -8.9 | -13.8 | -22.5 | -21.8 |
| Net margin | -45.83% | - | -58.81% | -40.24% | -7.99% | -21.33% | -11.2% | -6.39% | -8.68% | -14.23% | -14.06% |
| EPS 2 | -1.920 | -0.7700 | -2.670 | -1.860 | -0.3700 | -0.9700 | -0.5400 | -0.2600 | -0.4000 | -0.6500 | -0.6300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 1/27/22 | 11/3/22 | 1/26/23 | 4/27/23 | 7/18/23 | 11/2/23 | 2/8/24 | 5/8/24 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 143 | 277 | 251 | 150 | 70 |
| Net Cash position 1 | 473 | 214 | 11.7 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -1.24 x | -8.535 x | 4.799 x | 1.784 x | 0.4144 x |
| Free Cash Flow 1 | 255 | -172 | -282 | -181 | 106 | 1 | 31 | 101 |
| ROE (net income / shareholders' equity) | 37.1% | -13.3% | -49.2% | -65.4% | - | - | - | 30.4% |
| ROA (Net income/ Total Assets) | 15.7% | -6.17% | -17.8% | -14.9% | - | - | - | - |
| Assets 1 | 1,394 | 1,367 | 1,253 | 1,191 | - | - | - | - |
| Book Value Per Share 2 | 20.40 | 16.20 | 10.20 | 5.640 | 1.710 | 2.330 | 4.110 | 5.890 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 35.9 | 190 | 52.9 | 23.9 | - | 5 | 6 | 6 |
| Capex / Sales | 4.25% | 28.6% | 9.36% | 3.83% | - | 0.82% | 0.8% | 0.66% |
| Announcement Date | 1/30/20 | 1/28/21 | 1/27/22 | 1/26/23 | 2/8/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.58% | 79.03B | |
| +9.81% | 8.96B | |
| -10.76% | 5.19B | |
| +54.31% | 4.77B | |
| +11.19% | 4.26B | |
| -22.37% | 2.37B | |
| +12.49% | 2.3B | |
| -30.09% | 2.21B | |
| +20.63% | 2.17B |
- Stock Market
- Equities
- ORX Stock
- ORXO.Y Stock
- Financials Orexo AB